Pfizer knew Ivermectin protects against its deliberately added Endotoxin Jab Harms

Pfizer acquired Wyeth for $68 billion in 2009 as part of its plan to become the dominant player in Jabbing. What is the connection to Ivermectin?

Many have written about Ivermectin use being suppressed in treatment of Covid19, but have you heard before today that Pfizer, through its purchase of Wyeth in 2009, was a key driver in preventing Ivermectin rescue of Coronavirus and Jabbee victims? If so, please send me links to other authors so they can be properly included in the references.

Here is the front page preview of a paper published in 2008 by Wyeth Research, now renamed Pfizer for production of Covid19 jabs, along with its partners in China.¹

Note this paper is behind a paywall and not mentioned in the Wikipedia article.

For more on Pfizer acquisitions and its love of Endotoxin as Adjuvant see my earlier article.²

Pfizer has detailed knowledge of Endotoxin (LPS) Lethality

In 2008 the finding was:

Ivermectin Improved mouse Survival Rate induced by a Lethal dose of LPS. In addition, Ivermectin significantly decreased the production of TNF-a, IL-1ß and IL-6 in vivo and in vitro. Furthermore, Ivermectin suppressed NF-kB translocation induced by LPS.

You see listed some of the primary triggers of Death and lasting Misery caused by Jab induced Cytokine Storm³ that affects Women and their unborn children hardest.⁴

Pfizer Trial Subject Rescued with Ivermectin

In 2020 a Pfizer Clinical Trial subject, 56-year-old man who was given Placebo, contracted Pneumonia 17 days after receiving the second dose of Saline, and was rescued with a combination of drugs including Ivermectin, which was stopped when he tested negative for Covid19.⁵

Pfizer Jab Victim rescued with Ivermectin

Searching VAERS, I have so far found 1 reference to a Pfizer Jab victim treated with Ivermection to ameliorate the symptoms.

The 54-year-old man suffered Amnesia, Confusional state, Fatigue, Gait disturbance, Hallucination, Headache, Heart rate increased, Speech disorder, Tunnel vision, Vision blurred, Balance disorder, Dysstasia. There was observed improvement after 48 hours.

Other drugs he was given were Vitamin D3, Z(?), Quercitin, Aspirin and other supplements on advice of doctor.

Peru Study on Excess Deaths link to Ivermectin

A preprint study has now been peer-reviewed looking at Excess Deaths in Peru during the pandemic that shows strong correlation with mass Ivermectin dosing in a number of states and impact of supply withdrawal.⁶

Tell me what you think about that here or on Twitter

https://twitter.com/FluoridePoison

or Gettr

https://gettr.com/user/geoffpainphd

List of papers that have cited the Zhang 2008 paper can be found here.⁷

February 2024 Update

I have just discovered that Tess Lawrie wrote about this in 2022.⁸

August 2024 Update

Former Pfizer researcher Mike Yeadon who worked on Endotoxin with UK Minister for Science Patrick Vallance⁹ is now claiming Ivermectin is not worth the risks. Follow the discussion.¹⁰

December 2024 Update

I was alerted to a very interesting article discussing the Australian research published in early 2020 on Ivermectin.¹¹

The key document mentioned is the paper by reseachers at the Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity and Biomedicine Discovery Institute, Monash University.¹²

This is especially interesting because these scientists reported their isolation and successful cultivation of the Wuhan Covid19 virus.¹³

May 2026 Update

A useful large randomized clinical trial, published in 2024, found no value for Ivermectin in treatment of Covid19.¹⁴

Background

The evidence for whether Ivermectin impacts recovery, hospital admissions, and longer-term outcomes in COVID-19 is contested. The WHO recommends its use only in the context of clinical trials.

Methods

In this multicentre, open-label, multi-arm, adaptive platform randomised controlled trial, we included participants aged ≥18 years in the community, with a positive SARS-CoV-2 test, and symptoms lasting ≤14 days.

Participants were randomised to Usual Care, Usual care plus Ivermectin tablets (target 300–400 μg/kg per dose, once daily for 3 days), or Usual care plus Other interventions.

Co-primary endpoints were time to first self-reported recovery, and COVID-19 related hospitalisation/death within 28 days, analysed using Bayesian models. Recovery at 6 months was the primary, longer term outcome.

Trial registration: ISRCTN86534580.

Findings

The primary analysis included 8811 SARS-CoV-2 positive participants (median symptom duration 5 days), randomised to Ivermectin (n = 2157), usual care (n = 3256), and other treatments (n = 3398) from June 23, 2021 to July 1, 2022.

Time to self-reported recovery was shorter in the Ivermectin group compared with usual care (hazard ratio 1·15 [95% Bayesian credible interval, 1·07 to 1·23], median decrease 2.06 days [1·00 to 3·06]), probability of meaningful effect (pre-specified hazard ratio ≥1.2) 0·192).

COVID-19-related hospitalisations/Deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [−1% to 0·6%]), Serious Adverse Events (three and five respectively), and the proportion feeling fully recovered were similar in both groups at 6 months (74·3% and 71·2% respectively (RR = 1·05, [1·02 to 1·08]) and also at 3 and 12 months.

Interpretation

Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes.

Further trials of Ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.

Ivermectin Deaths and Birth Defects

After my article on Mebendazole Deaths and Birth Defects,¹⁵ my kind subscriber Raelene asked whether Ivermectin causes similar effects.

So I promised to delve further and sure enough a quick search of PubMed Ivermectin revealed Ivermectin is Genotoxic.

In 2011 researchers in Egypt investigated Ivermectin as a Teratogen.¹⁶

Abstract

Experiments in animals proved that P-glycoprotein (Pgp) forms a functional barrier between maternal and fetal blood circulation in the placenta, thus protecting the fetus from exposure to xenobiotics during pregnancy.

In this study we aimed to demonstrate the effects of administration of Ivermectin (anthelmentic drug, Pgp substrates), either alone or simultaneously with verapamil (Pgp inhibitor) in Wister Rats on fetal development, maternal bone marrow for detection of micronuclei (MN), chromosomal aberrations and mitotic index (MI) and embryonic liver cells for cellular proliferation indicated by MI, and bleeding from umbilical vessels for detection of embryonic micronuclei (MN).

The results revealed that administration of Ivermectin or verapamil at 6th through 15th day of gestation did not significantly altered fetal development.

While, co-administration of Ivermectin and verapamil clearly disturbed fetal development as indicated from abnormal feto-maternal attachment and a significant decrease in fetal weights and numbers.

Furthermore, co-administration of both drugs induced a significant increase in Resorption sites, post-implantation Loss and external, Visceral and Skeletal Abnormalities.

They also induced Genotoxicity in both dam and embryonic cells indicated by reduced mitotic index, increased number of micronucleated erythrocytes in both, and increased different types of chromosomal aberrations in dam cells, while Ivermectin alone show some genotoxic effect on somatic cells of dams and the embryos.

Verapamil induced reduction of embryonic mitotic index. We concluded combined treatment of Ivermectin and verapamil severely affect fetal genetic material and development and induced genotoxic effect in somatic cells of the dams.

A 2019 paper looking at Ivermectin as a Carcinogen and Mutagen in Fruit Fly (Drosophila melanogaster)and and Spiderwort aka Purple Heart (Tradescantia pallida).¹⁷ Note the extraordinary low concentrations used.

Abstract

Antiparasitic substances are chemicals used to control or kill endoparasites and ectoparasites. Based on the premise that Ivermectin (IVM) and Amoxicillin (AMX) are commonly considered in parasitic control in mammals, the present study aimed to evaluate the Carcinogenic and Genotoxic potential of different concentrations of IVM and AMX through the detection of epithelial tumor test in Drosophila melanogaster.

Third-instar larvae descending from the cross between wts/TM3, Sb¹ females and mwh/mwh males were treated with different concentrations of IVM (2.9, 5.8, 11.6 and 23.2 x 10^-17 mM) or AMX (1.37, 2.74, 5.48 and 10.9 x 10^-16mM).

The results revealed that IVM increased the frequency of epithelial Tumor in D. melanogaster considering all evaluated concentrations, while AMX showed no carcinogenic effect.

Furthermore, the Micronucleus (MN) test in Tradescantia pallida was used to evaluate the genotoxic effect of IVM and AMX. T. pallida individuals were exposed for 8 hours at different concentrations of IVM (5.71, 11.42, 22.84 and 45.68 x 10^-5mM) or AMX (5.13, 10.26, 20.52 and 41.05 x 10^-3mM).

Findings showed an increase in the frequency of micronuclei in T. pallida treated with 11.42, 22.84 and 45.68 x 10^-5mM of IVM. We conclude that chronic exposure to IVM is directly associated with events resulting from genetic instability (genotoxicity and carcinogenicity). On the other hand, AMX was neither carcinogenic nor genotoxic for D. melanogaster and T. pallida.

Another paper from 2019 showing Ivermectin is a Mutagen in mammals including sperm cells.¹⁸

Abstract

Ivermectin (IVM) is a broad-spectrum anti-parasite agent. It is extremely toxic to fish and aquatic life.

Some animals showed reduction in the fertility, the number of variable fetuses and sperm count following treatment with (IVM).

Therefore, the objective of the current work was to investigate the Mutagenicity of IVM on meiotic chromosomes of Mice.

The variations in protein fractions of blood serum were also studied using sodium Dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).

Animals received single injections only of 200 microgram/kg b.wt. for meiotic chromosome study. Whereas single and double treatment for serum protein examinations.

Analysis of the treated samples revealed significant increase in meiotic aberrations, 33.83% vs 5.8% for the control (P < 0.001).

Single injection induced much variation in the percentage area of the separated protein than that produced by double treatment. These findings supports the Mutagenicity of IVM, accordingly cautious use of IVM is advisable.

A 2009 paper from Argentina showing Ovaries are a target for Ivermectin.¹⁹

Abstract

The effects of Ivermectin (IVM) and its commercial formulation Ivomec (IVM 1.0%) were studied on Chinese Hamster Ovary (CHO(K1) cells by several genotoxicity [sister chromatid exchange (SCE) and single cell gel electrophoresis (SCGE)] and cytotoxicity [cell-cycle progression (CCP), mitotic index (MI), proliferative replication index (PRI), 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and neutral red (NR)] bioassays within the 1.0-250 microg/ml concentration-range.

While IVM and Ivomec did not modified SCE frequencies, they induced DNA-strand breaks revealed by SCGE.

An enhancement of slightly damaged cells and a decrease in undamaged cells were observed in IVM-treated cultures with 5.0-50.0 microg/ml.

In Ivomec((R))-treated cells, while an increase in slightly damaged cells was induced with 5.0-50.0 microg/ml, the damaged and undamaged cells increased and decreased only with 50.0 microg/ml.

Both compounds exerted a delay in CCP and a reduction in PRI when 25.0 microg/ml was employed whereas cytotoxicity was observed at higher concentration than 50.0 microg/ml.

No MI alteration was observed with 1.0-10.0 and 1.0-5.0 microg/ml of IVM and ivomec, respectively.

A concentration-related trend to an increase in MI was achieved within 1.0-10.0 microg/ml. An increase in the MI was induced in 10.0 microg/ml Ivomec-treated cultures.

A marked reduction of about 89% and 62% in regard to controls was observed with 25.0 microg/ml of IVM and Ivomec, respectively.

NR and MTT assays revealed a cell growth inhibition when 0.25-250.0 microg/ml of both compounds was employed.

The results highlighted that IVM and Ivomec exert both genotoxicity and cytotoxicity in mammalian cells in vitro, at least in CHO(K1) cells.

A 2024 paper from researchers in Pakistan, Saudi Arabia, USA, confirming Ivermectin is Genotoxic in Kidney cells.²⁰

Abstract

Ivermectin (IVM) is an anti-parasitic drug which is used for treating parasitic infestations. It has been used in humans for treating intestinal strongyloidiasis and onchocerciasis however, currently researchers are investigating its potential for treating coronavirus SARS-CoV-2.

Due to its broad-spectrum activities, IVM is being used excessively in animals which has generated an interest for researchers to investigate its toxic effects. Cytotoxic and genotoxic effects have been reported in animals due to excessive usage of IVM.

Therefore, this study aims to evaluate the cytotoxic and genotoxic effects of IVM on the Madin-Darby-Bovine-Kidney (MDBK) cell line by examining the expression of a DNA damage-responsive gene (OGG1).

Cytotoxicity of IVM was tested using an assay (MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), whereas the genotoxicity was evaluated using comet assay along with micronucleus assay.

Moreover, the gene expression of DNA damage response gene (OGG1) was measured by qRT-PCR, after extraction of RNA from the MDBK cell line using the TRIzol method and its conversion to cDNA by reverse-transcriptase PCR.

During the experiment, cell viability percentage was measured at different doses of IVM i.e., 25%, 50%, 75%, along with LC50/2, LC50 and LC50*2.

It was observed that the gene expression of OGG1 increased as the concentration of IVM increased.

It was concluded that IVM has both Cytotoxic and Genotoxic effects on the MDBK cell line.

Furthermore, it is recommended that studies related to the toxic effects of IVM at molecular level and on other model organisms should be conducted to combat its hazardous effects.

1. Zhang X, et al. 2008. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. https://link.springer.com/article/10.1007/s00011-008-8007-8

2.

3.

4.

5. 19MB file 125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive available for free download from https://phmpt.org/pfizer-16-plus-documents/

6. Chamie JJ et al. 2023. COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State. https://www.cureus.com/articles/172991-covid-19-excess-deaths-in-perus-25-states-in-2020-nationwide-trends-confounding-factors-and-correlations-with-the-extent-of-ivermectin-treatment-by-state

7. https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed_citedin&from_uid=19109745

8. Why Are They So Desperate To Keep Little Old Ivermectin From You?

9.

10. The anti-Ivermectin crowd, they can't be serious can they?

11. Ivermectin: Op or Prank?

12. Leon Caly , Julian D Druce, Mike G Catton , David A Jans, Kylie M Wagstaff. 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. https://www.sciencedirect.com/science/article/pii/S0166354220302011

13.

14. Gail Hayward, Ly-Mee Yu, Paul Little, Oghenekome Gbinigie, Milensu Shanyinde, Victoria Harris, Jienchi Dorward, Benjamin R. Saville, Nicholas Berry, Philip H. Evans, Nicholas P.B. Thomas, Mahendra G. Patel, Duncan Richards, Oliver V. Hecke, Michelle A. Detry, Christina Saunders, Mark Fitzgerald, Jared Robinson, Charlotte Latimer-Bell, Julie Allen, Christopher C. Butler. 2024. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes. https://www.sciencedirect.com/science/article/pii/S0163445324000641

15.

16. Ibrahim M el-Ashmawy, Abeer F el-Nahas, Aida E Bayad. 2011. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci. 90(1):116-23. doi: 10.1016/j.rvsc.2010.05.020.

17. Francielle Aparecida de Sousa, Cássio Resende de Morais, Jéssica Soares Vieira, Lavínia Sales Maranho, Francielli Lara Machado, Samanta Pereira, Lilian Cristina Barbosa, Humberto Eustáquio Coelho, Carlos Fernando Campos, Ana Maria Bonetti. 2019. Genotoxicity and carcinogenicity of ivermectin and amoxicillin in vivo systems. Environ Toxicol Pharmacol. 70:103196. doi: 10.1016/j.etap.2019.103196. https://pubmed.ncbi.nlm.nih.gov/31152944/

18. Karima Mohammad Sweify, Iman Abd El Moneim Darwish, Dalia Demerdash Abd El Monem Hafez. 2019. The mutagenic effects of ivermectin in germinal cells and serum protein of the mouse. https://pubmed.ncbi.nlm.nih.gov/31081777/

19. G Molinari, S Soloneski, M A Reigosa, M L Larramendy. 2009.In vitro genotoxic and cytotoxic effects of ivermectin and its formulation ivomec on Chinese hamster ovary (CHOK1) cells. J Hazard Mater. 165(1-3):1074-82. doi: 10.1016/j.jhazmat.2008.10.083. https://pubmed.ncbi.nlm.nih.gov/19056171/

20. Muhammad Muddassir Ali, Zainab Farhad, Muhammad Wasim, Sohail Raza, Mikhlid H Almutairi, Kainat Zahra, Muhammad Usman Saleem, Khalid Mehmood. 2024. Evaluation of genotoxic effect via expression of DNA damage responsive gene induced by ivermectin on MDBK cell line. PLoS One. 19(5):e0296255. doi: 10.1371/journal.pone.0296255. https://pubmed.ncbi.nlm.nih.gov/38701093/